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Abstract - Pharmaceutical expert information is 
characterized by steady increase in extent and com-
plexity as well as by strong interweavement and 
penetration with interdependent references. These 
properties suggest the utilization of modern hyper-
media technology, organizing knowledge as a net-
work of linked pieces, enabling more intuitive, 
faster and easier navigation within the growing 
information space. There is a need for a suitable, 
role oriented external representation of pharmaceu-
tical expert information. 
The application of pharmaceutical expert informa-
tion when analyzing medications for contra-
indications and interactions is mainly mechanical in 
nature. It requires to follow references and to com-
pare codes. The electronic availability of medica-
tion information, which is often forced by drug 
dispensing systems, is not exhausted when these 
procedures are performed manually at the screen. 
There is a need for automatization of these proce-
dures. This automatization requires a suitable inter-
nal representation of pharmaceutical expert infor-
mation. 
The universality of pharmaceutical information 
systems leaves open their conceptual environment. 
The different kinds of application scenarios pose 
strong requirements on the formalization of expert 
information. A universal representation has to be 
found which captures the nature of pharmaceuticals 
including common properties of drug classification 
systems. The diversity of the latters within the dif-
ferent healthcare organisations is to be regarded as 
the most serious barrier aggravating global commu-
nication within the healthcare system. 
I. MOTIVATION 
The main concern of healthcare management has 
ever been embodied by two conflicting goals. These 
are improving care quality while reducing care 
costs. Information technology already has proven 
its positive impact on both goals. While general 
administrative tasks are being performed more 
efficiently for some decades, expert oriented sys-
tems are entering the medical domain with increas-
ing support capabilities for domain specific thera-
peutic procedures leading to more secure and effi-
cient therapy planning, monitoring and control. 
The demands on quality and effectiveness of care 
are posed by social, legal and political areas, result-
ing in growing expectation, uncertainty and pres-
sure concerning health care professionals’ use of 
expert information. These circumstances are corner-
ing medical practitioners. A variety of role specific 
information problems may be identified which 
finally can be attributed to the non-availability of 
suitable represented expert information as well as to 
missing automatization of medical procedures. In 
their entirety they indicate two major information 
problems in healthcare.  
The representation problem consists of the lack of a 
universal representation of pharmaceuticals which 
formally describes their common properties as well 
as their behavior within groups of simultaneously 
applied drugs. Internal representation affects granu-
larity and precision of information as well as the 
functionality of the application system. External 
representation affects suitability of access and navi-
gation mechanisms, which depend on the user’s role 
and situation. An internal representation may meet 
the needs of many applications, while an external 
representation can only be as suitable as the internal 
representation allows. 
The communication problem refers to the commu-
nication capabilities of a representation delivered 
by a solution of the previous problem. There is 
nearly no benefit of a pharmaceutical information 
model if information is not suitable for transporta-
tion. This means that the impact of an internal rep-
resentation reaches interorganizational cooperation 
capabilities. This affects particularly the diversity 
of semantic reference systems used by local repre-
sentations. The communication problem consists of 
finding means to enable organizations to exchange 
information with a minimum of human interven-
tion. 
As the information jungle continues to grow health-
care costs and treatment quality change to worse. 
The patient has to bear the consequences. While his 
contribution on treatment costs increases, no one 
can guarantee that the medication designed by the 
physician is optimal in both therapeutic and eco-
nomic sense. For instance, many expensive com-
mercial brand products of major manufacturers may 
be substituted by more beneficial, therapeutically 
equivalent generics, but without this information at 
his fingertips the physician will continue to pre-
scribe products with concise and habitual names. 
II. APPLICATION DOMAIN 
The application domain targeted by pharmaceutical 
information systems includes any medical subject 
area affected by information on properties of phar-
maceutical products. This comprises the treatment 
situation at the physician’s desktop, drug dispensing 
procedures in hospital pharmacies, pharmaceutical 
consultation at the drugstore as well as patient 
home information. Although differences exist 
among role and situation specific external represen-
tations of user oriented information, any application 
of pharmaceutical information systems relates to 
some properties of pharmaceuticals. 
This universal applicability of pharmaceutical in-
formation systems leads to their architectural role 
as a subsystem within a not further specified su-
perordinated medical information system. Many 
applications may exist. Thus, these systems are 
highly polymorphic in nature and the need for a 
single universal internal representation can be justi-
fied with reusability, integrity and universality. The 
role leaves open any assumptions of the application 
domain. Any usage is specific to the superordinated 
application system. However, three principle appli-
cations of pharmaceutical information systems may 
be considered. 
Medication Analysis is a procedure that aims to 
identify any critical problems within a given input 
medication. A set of problems is computed, each of 
which may be a contra-indication, an interaction or 
an overdose. It is desirable that this procedure also 
adds links to further information found in local or 
external documents. Medication analysis can sig-
nificantly improve security of drug dispensation. 
Medication Transformation is a procedure that aims 
to construct a new medication which is therapeuti-
cally equivalent to an input medication, and which 
meets certain optimization criteria. The most bene-
ficial criteria refer to cost reduction. Then, some of 
the prescribed drugs are substituted with the most 
beneficial but therapeutically equivalent products 
available. This procedure relates to Managed Care 
(Prescription Benefit Management), as is practiced 
in the United States as an intervention of insurance 
companies in the prescriptions of physicians. Medi-
cation transformation can significantly improve 
prescription efficiency. 
Medication Synthesis is a procedure that aims to 
construct a medication based on its desired proper-
ties. The input is a specification of these properties 
in terms of wanted and optionally unwanted effects, 
and the output is a medication with a maximum of 
conformity with the specification and a minimum 
of undesired properties, concerning both therapeutic 
and economic issues. Until now, medication analy-
sis is to be regarded as a theoretical application and 
is mentioned because it formally is the opposite 
procedure to medication analysis. 
The application goal for the physician seems to be 
clear: The goal is to be able to define an optimal 
medication for a patient with a given disease within 
a given situation. In this context the term ’optimal’ 
refers to both the therapeutic suitability and the 
economic effectiveness of a medication. While this 
task is impossible to accomplish manually in rea-
sonable time, distributed information services could 
provide techniques to compare costs and therapeu-
tic properties of pharmaceutical products automati-
cally. For instance, the physician could select some 
brand drug and ask for any generics with the same 
composition and effects. 
Within the scope of a hospital pharmacy two prin-
cipal uses of pharmaceutical expert information 
may be distinguished. The main purpose is the drug 
dispension, usually performed automatically by a 
machine controlled by a special software system. 
Up to date this is the primary reason for electronic 
representation of medication information. The sec-
ond task of the pharmacy is to check each medica-
tion for certain errors and inconsistencies, e. g. 
contra-indications or serious interactions. This 
analysis, which is regular and mechanical in nature, 
is still done manually. Pharmacists sit in front of the 
screen and analyze medications using a book. There 
is a need for the automatization of medication 
analysis. 
From the patient’s point of view there is a need for 
information on the drugs he takes, on their usage 
and influence on his disease. This information has 
to be presented in a way understandable by the 
patient. This means that descriptions and instruc-
tions should not contain expert terminology and 
should not require a deeper understanding of the 
medical domain. This property of presentation has 
great influence on the patient’s discipline. Apart 
from medical or scientific oriented scales, good 
patient information must be regarded as one com-
ponent of a good therapy. 
For any expert oriented application it is desirable to 
access local and external documents, which are 
relevant to a given situation or which explain some 
statement made by a system. For instance, if medi-
cation analysis reports a critical interaction, links 
should also be presented allowing the user to im-
mediately access further information from standard 
literature or product documentation. This also sug-
gests an application for medical students where a 
system can analyze their prescriptions and generate 
hints and advices. 
III. PROBLEMS OF INFORMATION MANAGEMENT 
Healthcare in general is characterized by high spe-
cialization and division of labour. Many profes-
sionals practice services for many patients, and data 
is produced at many places and may be needed at 
many others. Mobility of patients and the free 
choice of medical practitioner makes this situation 
worse, as the individual’s moves through the health-
care system leave trails consisting of distributed 
heterogeneous medical data. Thus, mobility of 
patients requires the mobility of data. 
Pharmaceutical product information is distributed 
and heterogeneous in a similar way as is patient 
data. Furthermore, it is subject to fast change and 
reconditioning. It partly refers to patient medical 
data, as is with contra-indications or age specific 
dosage instructions. As a conclusion one may no-
tice strong interconnections and dependencies be-
tween patient specific medical data and pharmaceu-
tical product information. Product documentation 
refers to patient specific conditions, and patient 
therapy documentation refers to applied products. 
The scattering and heterogenity of both patient 
history data and pharmaceutical product informa-
tion lead to a variety of information problems for 
the different actors in the healthcare system. These 
problems refer to the availability of information in 
general and to the suitability of its representation in 
particular. Any of these role specific information 
problems may finally be attributed to the two major 
problems of healthcare information management: 
representation and communication of expert and 
product information. 
The physician’s information problem refers to the 
treatment situation, where medications are com-
posed and pharmaceutical products are compared. 
Far too much information would have to be taken 
into account in order to determine the most effec-
tive drugs regarding to both therapeutic suitability 
and economic benefit. The problem consists of not 
having means to consult all of the available infor-
mation sources manually, without the help of in-
formation technology. 
The pharmaceutical company’s information prob-
lem refers to both the communication of product 
information to the practitioners who prescribe it and 
the reflow of information gained through observa-
tion and experience. There are incentives for the 
industry to pass actual findings delivered by re-
search and practice to the practitioners. There are 
also incentives to get informed on unknown drug 
effects. 
The insurance company’s information problem 
refers to the economic optimization of prescriptions 
through substitution of products. Under care and 
attention of the critical constraint of therapeutic 
equivalence the substitution of brand products with 
generics bears a high potential of cost saving but 
effect keeping transformation. But this transforma-
tion requires knowledge and is desired to be per-
formed automatically. 
The patient’s information problem refers to his 
situation at home, after being undeceived and in-
structed concerning drug application by the physi-
cian. In general, additional questions arise within 
this situation and many aspects on disease, treat-
ment, medication and instructions are not covered 
by the short and expensive consultation. From the 
patient’s point of view there is a need to be able to 
get informed on these aspects whenever he wants 
to. From the physician’s point of view there also is a 
need to delegate standard explanations to public 
media. 
In the advent of the approaching information age 
these information problems would not exist, if there 
were reasonable means of applying information 
technology on the use of pharmaceutical expert 
information. This leads to the very question of 
information exchangeability within the healthcare 
sector regarding to pharmaceutical products. As 
with any other kind of information on entities, the 
attributes of which are represented as references 
into certain external classifications, drug informa-
tion may only be interpreted in regard to respective 
semantic reference systems. 
There is one major conclusion to be drawn from the 
variety of role specific information problems illus-
trated above. They have in common the need for 
information retrieval and processing concerning 
pharmaceutical products as well as its preparation 
in a suitable external representation. It seems that 
the reason for missing availability of pharmaceuti-
cal information is not its absence but the different 
languages existing in healthcare. Starting from that 
today there are means to transport information from 
one site to another, one may realize that the prob-
lem cannot be the absence of communication infra-
structures. The answer is much more simple and 
complex at the same time: The problem lays within 
the information itself. The most serious problem 
blocking global communication in healthcare re-
sults from the lack of common languages. 
IV. MODELING PHARMACEUTICAL EXPERT 
INFORMATION 
The formation of a universal information model for 
pharmaceutical products and their properties relates 
to domain specific coherencies concerning drugs 
and chemical substances as well as many aspects of 
software engineering in general. The former in-
volves some understanding of the applications and 
effects of pharmaceuticals as well as the interde-
pendencies among the different kinds of properties 
a drug may have. The latter involves design strate-
gies and modeling techniques which meet today’s 
requirements on compactness, reusability, flexibil-
ity and consistency of an internal representation. 
Any pharmaceutical information model will be 
measured by its applicability in both fields. 
The most fundamental awareness of any drug char-
acteristics describing information model must be 
the distinction of two kinds of properties which 
may be regarded in different layers. These are 
properties, which refer to a pharmaceutical product 
in isolation, on the one hand, and its behavior 
within the society of a group of drugs, on the other 
hand. The former are constant for a drug and will 
not change. The latter depends on the combination 
of drugs, the patient’s state and on many other as-
pects of its situation. This distinction may be cap-
tioned by the following assignments. 
Static pharmaceutical information refers to drug 
properties which will not change when the drug’s 
role within a medication or therapy changes. These 
properties include name, manufacturer, composition 
as well as obligatory information. Some of these 
properties may be represented as isolated data ele-
ments. This means that they are consistent on their 
own, and their interpretation is independent of cer-
tain external formalisms. Other properties (e. g. 
indications) are to be regarded as references into 
external semantic reference systems, and may not 
be interpreted without the awareness of these for-
malisms. For instance, an indication can be re-
garded as a reference into an indication classifica-
tion system. Of course one could model such prop-
erties as simple text fields. But in this case, only 
humans could understand this information. 
Dynamic pharmaceutical information refers to drug 
characteristics concerning their behavior within a 
medication, especially the interplay of therapeutic 
effects. These characteristics are dynamic in nature 
because they may change with a drug’s membership 
within different medications. They depend on vari-
ous parameters of a clinical situation, including 
disease, patient demographic data, and, of course, 
other prescriptions. A drug may change the effect 
of other drugs and its effects may be changed by 
others. 
A universal pharmaceutical information model 
should not refer to some specific classification 
system. Instead, it should refer to an abstract meta-
structure which is capable of being instantiated by 
any classification. Groupings, as such meta-
structures will be called in the following, are ab-
stract trees representing inheritance hierarchies with 
implicit IS-A semantics. Inheritance is the principal 
property these structures provide: Any information 
associated with some group is also valid for each of 
its subgroups. 
The universality of a pharmaceutical information 
model results from two major design properties. 
First, not one but a set of groupings reside in the 
knowledge base, providing a language for describ-
ing drug properties. Secondly, any drug may be 
assigned into not one but into any number of groups 
belonging to different groupings. The first design 
issue (multiple groupings) allows the consideration 
of different classification strategies and therefore 
the provision for different applications. Each group-
ing represents some specific view on the domain, 
focussing specific attributes of pharmaceutical 
products. The second design issue (multiple as-
signments) allows a maximum of precision con-
cerning the representation of drug properties. One 
single assignment represents some feature of a 
drug. The entirety of assignments characterizes a 
drug. 
Groupings provide the vocabulary to specify rela-
tions between groups of drugs. Conflicts may be 
defined which relate one group to another and state 
that a combination of respective group members 
may cause a critical interaction. Additional condi-
tions may be attached to such a conflict (e. g. indi-
cation, dosage) that further refine the set of cases 
where a conflict indicates an interaction. In this 
way, medication analysis may be reduced to the 
evaluation of group combinations. 
Analytic processing capabilities of pharmaceutical 
expert information belong to the most beneficial 
properties a suitable information model can pro-
vide. Examples for their applications include auto-
matic medication analysis, product comparison and 
even medication analysis. There is no loss in func-
tionality comparing to low structured representa-
tions, because simple text documents may always 
be generated from precise representations. In addi-
tion, such a generation may take respect to the 
user’s role and situation through inclusion and ex-
clusion of information components, detail level 
determination and through terminology selection. 
 
The universality of a pharmaceutical information 
model based on the abstract grouping concept pre-
sented above may be illustrated by the following 
scenario. Assume a hospital pharmacy which is 
responsible for the daily validation of medication 
information. The pharmacy uses their own drug 
classification system which is tailored to the set of 
locally applied pharmaceuticals. The automation of 
medication analysis is desired on the condition that 
the local classification system needs not to be re-
placed. 
A medication analysis system based on the abstract 
grouping model meets these requirements. It sug-
gests the following installation steps. First, the local 
classification system is entered into the system as a 
set of groups organized in a hierarchical structure. 
Secondly, the set of drugs is acquired focussing on 
static information and, thus, resulting in a linear list 
of records. Then, drugs are characterized by assign-
ing one or more groups to each drug. Finally, con-
flicts are defined by selecting sets of groups the 
elements of which form a critical combination. 
Then, medication analysis can be performed auto-
matically. The system may be configured to let pass 
standard medications and to identify occurrences of 
critical drug combinations. In these cases the sys-
tem may notify the users and the medication can be 
reviewed manually. From the pharmacist’s point of 
view, automatic medication analysis can signifi-
cantly reduce the number of cases which need hu-
man attention, while the local classification system 
can be used to specify the electronic knowledge 











Interplay between objects, groups and conflicts 
 
V. FURTHER RESEARCH 
The formation of a universal pharmaceutical infor-
mation model may suggest an internal representa-
tion within the context of pharmaceutical informa-
tion systems, but it cannot provide solutions for 
problems resulting from the distinct roles, views 
and interests among the different actors in the 
healthcare system. Political agreement of common 
organization of expert information cannot be con-
cern of medical informatics. 
The unification problem of healthcare refers to the 
chasm between universality and specifity of seman-
tic reference systems. A universal classification 
system will not be suitable for specific applications 
and a classification which is suitable for a specific 
application will not be suitable for others. There 
seems to be no way out: The unification of seman-
tic reference systems appears to be the only solu-
tion. 
The standardization problem refers to the develop-
ment of semantic reference systems and to the insti-
tutionalization of their coordination. Starting from 
that diversity exists between different applications, 
roles and interests, it would be desirable to have 
these differences controlled by a global institution. 
The question is: Who will act as a global standards 
defining institution and which interests will be 
covered? 
The major problem of internal drug representation 
is the formation of a universal information model. 
This in turn leads to the challenge of developing 
one universal drug classification system. Since any 
classification is a direct result of respective design 
strategies and focused applications, a universal drug 
classification system must be the result of common 
design strategies and common goals. The question 
is: What should be the major design strategy 
regarding to a universal drug classification system? 
The universality of scope claimed by uniformity of 
representation leads to the property of suitability. A 
universal classification system is exhaustive with 
regard to the focused domain, and in all probability 
it is oversized for small applications. This holds for 
monoaxial classifications. There is no proof for the 
theoretical existence of a universal (possibly multi-
axial) classification which meets suitability of all 
applications. The question is: Can a universal 
pharmaceutical classification system meet the needs 
of specialized applications? 
In the past many innovative concepts were devel-
oped to help overcome information problems in 
healthcare. Many projects failed at the requirements 
of data security. The latter has emerged to a politi-
cal rather than a technical barrier of healthcare 
communication. In many cases, data security re-
quirements for technical procedures exceed the 
requirements for equivalent manual procedures. For 
instance, the German electronic health insurance 
card was originally intended to store medical data 
on a patient’s history. Today these cards do not 
contain any medical data. Under full agreement to 
the importance of data security, the question is: 
Will data security issues continue to barrier infor-
mation processing and communication in health-
care? 
Taking the diversity and heterogenity of pharma-
ceutical classification systems for granted and im-
mutable one possibility remains. This is the auto-
mated mapping of semantic references between 
different classification systems. This means that a 
reference into some classification may be automati-
cally translated into a reference into another classi-
fication. Since almost any pair of classification 
trees consists of similar layers, such a translation is 
always possible. However, information loss is the 
price for this automated mapping, when differences 
between classifications are too large. 
VI. DISCUSSION 
The two-sided challenge of representation and 
communication of pharmaceutical product informa-
tion illustrates the interdependency between infor-
mation modeling and distribution in healthcare. 
Both dimensions affect the application of expert 
information. A pharmaceutical information model 
may be suitable for some applications and it may be 
suitable for communication. But it seems to be very 
difficult to design a model which is suitable regard-
ing both dimensions. 
As with any kind of information which is used in 
different application contexts, pharmaceutical 
product information may be structured in many 
ways, resulting in different and in most cases in-
compatible reference systems. Pharmaceuticals may 
be classified by indication or contra-indication, 
their composition of chemical substances, their 
pharmacological effects or therapeutic use. Any of 
these characteristics implicates certain applications 
of the resulting classification. In general, a classifi-
cation system incorporates an application specific 
strategy of decomposition. Strong interdependen-
cies exist among properties like universality, com-
plexity and suitability. 
These circumstances suggest doubts on the theo-
retical existence of a universal classification system 
for a knowledge domain covering all application 
scenarios and meeting all requirements. These 
doubts get stronger under the consideration of suit-
ability, which correlates extent and complexity of a 
classification system with extent and complexity of 
an application scenario. For instance, the german 
drug classification system provided by the ’Rote 
Liste’ covers about 9000 commercial pharmaceuti-
cal products, while small hospital pharmacies deal 
with only about 800 drugs, which in their combina-
tion cover all medications. It seems that a universal 
classification system for a knowledge domain, 
which is exhaustive in nature, must be oversized for 
the needs of small applications. 
A scientific point of view enlightens many aspects 
of domain specific classification development 
which identify the real problems predominantly 
within the expert domain itself. Many applications 
of classification systems make use of their hierar-
chical structure and object-oriented nature, if given. 
In fact, properties of classifications are applied in 
terms of inheritance and polymorphism. There exist 
reasonable doubts on the awareness of the object-
oriented modeling paradigm in the community of 
classification developing medics. This can be 
proved with several classifications developed in 
medicine, which in general match the requirements 
of knowledge representations, but fail at the vital 
design properties (e. g. ICD, ICD-O, ATC). 
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